Woven EndoBridge device effective for treating ruptured and unruptured aneurysms in all intracranial locations<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Jan. 13, 2022 (HealthDay News) — Real-world use shows the Woven EndoBridge (WEB) device is safe and effective for treating brain aneurysms, according to a research letter published online Dec. 17 in Stroke<\/em>.<\/p>\n Adam A. Dmytriw, M.D., from Massachusetts General Hospital in Boston, and colleagues presented multicenter data to aid decision-making and prognostication when considering the use of a WEB device. The analysis included both ruptured and unruptured aneurysms (683 in 671 patients) in all intracranial locations treated at 22 academic institutions with the WEB device. <\/p>\n The researchers found that at a median 11 months of follow-up, adequate occlusion was seen for 85.7 percent of aneurysms and complete occlusion occurred in 57.8 percent. No re-ruptures occurred. Overall, 7.8 percent of aneurysms required retreatment and 7.5 percent of procedures had thromboembolic complications, of which 4 percent were symptomatic and 2 percent were permanent. Hemorrhagic complications were documented in 3 percent of procedures. Lower rates of adequate aneurysm occlusion were significantly associated with minor compaction (adjusted odds ratio [aOR], 0.45; 95 percent confidence interval, 0.24 to 0.86; P = 0.015) or major compaction (aOR, 0.25; 95 percent confidence interval, 0.11 to 0.57; P = 0.001) versus no compaction. Immediate remnant aneurysm (aOR, 0.45; 95 percent confidence interval, 0.18 to 1.00; P = 0.065) at the end of procedural digital subtraction angiography was associated with less adequate aneurysm occlusion on last follow-up compared complete occlusion.<\/p>\n “Patients who are not suitable for open aneurysm surgery or who have recently had a life-threatening rupture and would be at high risk for additional bleeding if treated with conventional endovascular techniques due to the need for blood thinners, now have a viable treatment option,” Dmytriw said in a statement.<\/p>\n Several authors disclosed financial ties to the medical device industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n